TipRanks on MSN
Vor Biopharma Unveils Promising Phase 3 Trial Results
Vor Biopharma ( (VOR) ) has provided an update. On October 28, 2025, Vor Biopharma Inc. hosted a webcast to present 48-week Phase 3 clinical trial data from China for telitacicept in treating primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback